

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 11, 2006 <i>(use as many sheets as necessary)</i>				Complete if Known 10 579078	
Application Number		Unassigned			
Filing Date		11/5/2004			
First Named Inventor		Hervé GROUX			
Group Art Unit		Unassigned			
Examiner Name		Unassigned			
Attorney Docket Number		065691-0443			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	2002/034500	A1	LEVINGS et al.	03/21/2002	
	A2	2004/0191235	A1	GROUX et al.	09/30/2004	
	A3	5,498,420	A	MENTRUP et al.	03/12/1996	
	A4	6,277,635	B1	RONCAROLO et al.	08/21/2001	
	A5	6,884,410	B1	RONCAROLO et al.	04/26/2005	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	A6	WO	97/42324	A	Schering Corporation	11/13/1997	
	A7	WO	02/092793	A	Institute National de la Sante et de la Recherche Medicale - INSERM	11/21/2002	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A8	AKDIS et al., "Inhibition of T helper 2-type responses, IGE production and eosinophilia by synthetic lipopeptides," European Journal of Immunology, October 2003, vol. 33, no. 10, pp. 2717-2726.	
	A9	FOUSSAT et al., "A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation," Journal of Immunology, November 15, 2003, vol. 171, no. 10, pp. 5018-5026.	
	A10	GROUX, H., "Type 1 T-regulatory cells: their role in the control of immune response," Transplantation, May 15, 2003, vol. 75, no. 9, SUPPL, pp. 8S-12S.	
	A11	PICHLER et al., "Cellular and molecular pathophysiology of cutaneous drug reactions," American Journal of Clinical Dermatology, 2002, vol. 3, no. 4, pp. 229-238.	
	A12	ROUAIX et al., "Effect of a lipopeptidic formulation on macrophage activation and peptide presentation to T cells," Vaccine, 1994, vol. 12, no. 13, pp. 1209-1214.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.